MedPath

Fatigue a Long COVID-19 Symptom Substudy of FSC19-KN Trial

Completed
Conditions
SARS-CoV2 Infection
Interventions
Other: Fulfilling Questionaires
Registration Number
NCT04883190
Lead Sponsor
Hegau-Bodensee-Klinikum Singen
Brief Summary

Prospective, controlled follow-up observation of SARS-CoV-2 positive patients with regard to the aspect of fatigue (cognitive / motor) and psychological disorders in the areas of anxiety, depression and somatization.

Detailed Description

After informed consent is given, questionnaires will be obtained 6 months and 12 months after infection. For analyzing cognitive and motor fatigue, classified in mildly, moderately or severely fatigue the questionnaire will be calculated by The Fatigue Scale for Motor and Cognitive Functions (FSMC).

And the occurrence of Major Depressive Disorder, other depressive Syndrome or Panic syndrome measured by Brief Patient Health Questionnaire.

The FSC19-KN trial already included patients with positive test for SARS-CoV-2 by PCR and volunteers with negative SARS-CoV-2 antibody testing. Verification of exclusion criteria had been completed in the main trial FSC19-KN. After the informed consent to participation in the sub-study is given all inclusion modalities are fulfilled.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
353
Inclusion Criteria

Patient must meet ALL of the following criteria.

  1. Participation in the FSC19-KN study
  2. Consent to participate in the survey
Exclusion Criteria
  1. Failure to give consent to the survey

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
1. after SARS-CoV-2 infectionFulfilling QuestionairesAll participants in the study and control group of the FSC19-KN study will be contacted either by email or by post. We plan to write to around 200-250 patients after SARS-CoV-2 infection and 200-250 test subjects in the control group.
2. control group with negative antibody testFulfilling QuestionairesAll participants in the study and control group of the FSC19-KN study will be contacted either by email or by post. We plan to write to around 200-250 patients after SARS-CoV-2 infection and 200-250 test subjects in the control group.
Primary Outcome Measures
NameTimeMethod
Presence of fatigue12 month after infection

Evaluate cognitive and motor fatigue classified in mildly, moderately or severely fatigue

Secondary Outcome Measures
NameTimeMethod
Occurrence of Major Depressive Disorder, other depressive Syndrome or Panic syndrome.12 month after infection

analyzed by PHQ-D (brief)

Trial Locations

Locations (1)

Hegau Bodensee Klinikum Singen

🇩🇪

Singen, BW, Germany

© Copyright 2025. All Rights Reserved by MedPath